Schering-Plough is purchasing prescription-drug and animal-health products manufacturer Organon BioSciences from parent Akzo Nobel in a deal worth $14.4 billion (more information here). Organon might not be a familiar name to many U.S. veterinarians, but it’s animal health division, Intervet, is. The Animal Pharm: Publisher’s Notes blog notes that the purchase could “catapault Schering-Plough to the top of the animal health industry league table” over Pfizer and Merial.